Literature DB >> 10851770

Caregiver quality of life after autologous bone marrow transplantation.

D Boyle1, L Blodgett, S Gnesdiloff, J White, A M Bamford, M Sheridan, R Beveridge.   

Abstract

Bone marrow transplantation (BMT) is a unique cancer therapy characterized by its novelty, intensity, and toxicity. Although families have been identified as having a critical influence on patient adaptation during the acute phase of BMT, minimal attention has been paid to their experiences during extended survivorship. This article reviews findings from a descriptive study on quality of life in primary caregivers of adult autologous bone marrow transplantation (AuBMT) survivors after acute hospitalization. Caregiver perceptions of their survival are delineated in an effort to characterize the dynamics of family recovery after BMT. Specifically, caregivers of AuBMT survivors require ongoing assistance to maintain their primary support role after BMT.

Entities:  

Mesh:

Year:  2000        PMID: 10851770     DOI: 10.1097/00002820-200006000-00006

Source DB:  PubMed          Journal:  Cancer Nurs        ISSN: 0162-220X            Impact factor:   2.592


  13 in total

1.  Emotion regulation therapy for cancer caregivers-an open trial of a mechanism-targeted approach to addressing caregiver distress.

Authors:  Allison J Applebaum; Aliza A Panjwani; Kara Buda; Mia S O'Toole; Michael A Hoyt; Adam Garcia; David M Fresco; Douglas S Mennin
Journal:  Transl Behav Med       Date:  2020-05-20       Impact factor: 3.046

2.  Phenotypic and molecular characteristics associated with various domains of quality of life in oncology patients and their family caregivers.

Authors:  Kimberly E Alexander; Bruce A Cooper; Steven M Paul; Patsy Yates; Bradley E Aouizerat; Christine Miaskowski
Journal:  Qual Life Res       Date:  2016-05-09       Impact factor: 4.147

3.  Long-term implications of autologous HCT for caregiver quality of life: how does the survivor's health matter?

Authors:  Irena Stepanikova; Karen Powroznik; Karen Cook; D Kathryn Tierney; Ginna Laport
Journal:  Support Care Cancer       Date:  2018-06-20       Impact factor: 3.603

4.  Distress screening in allogeneic hematopoietic stem cell (HSCT) caregivers and patients.

Authors:  Margaret Bevans; Leslie Wehrlen; Olena Prachenko; Karen Soeken; James Zabora; Gwenyth R Wallen
Journal:  Psychooncology       Date:  2011-02-01       Impact factor: 3.894

Review 5.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Patient-Centered Outcomes Working Group Report.

Authors:  Margaret Bevans; Areej El-Jawahri; D Kathryn Tierney; Lori Wiener; William A Wood; Flora Hoodin; Erin E Kent; Paul B Jacobsen; Stephanie J Lee; Matthew M Hsieh; Ellen M Denzen; Karen L Syrjala
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-19       Impact factor: 5.742

6.  Elevated peri-transplant distress in caregivers of allogeneic blood or marrow transplant patients.

Authors:  Teresa L Simoneau; Susan K Mikulich-Gilbertson; Crystal Natvig; Kristin Kilbourn; Janet Spradley; Rachel Grzywa-Cobb; Samuel Philips; Peter McSweeney; Mark L Laudenslager
Journal:  Psychooncology       Date:  2013-02-25       Impact factor: 3.894

Review 7.  Care for the cancer caregiver: a systematic review.

Authors:  Allison J Applebaum; William Breitbart
Journal:  Palliat Support Care       Date:  2012-10-10

Review 8.  A scoping review of caregiver burden during allogeneic HSCT: lessons learned and future directions.

Authors:  A J Applebaum; M Bevans; T Son; K Evans; M Hernandez; S Giralt; K DuHamel
Journal:  Bone Marrow Transplant       Date:  2016-06-13       Impact factor: 5.483

Review 9.  Psychological issues of stem cell transplant.

Authors:  Liz Cooke; Robin Gemmill; Kate Kravits; Marcia Grant
Journal:  Semin Oncol Nurs       Date:  2009-05       Impact factor: 2.315

10.  Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients.

Authors:  Kareem Jamani; Lynn E Onstad; Merav Bar; Paul A Carpenter; Elizabeth F Krakow; Rachel B Salit; Mary E D Flowers; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2018-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.